Table 1.
Cytotoxicity screening of the thiazole-triazole hybrides 3–8 against normal human lung fibroblasts (Wi-38), NSCLC cells (A549), and their selectivity index (SI) values.
| Compound No. | Structure | Wi-38 |
A549 |
||
|---|---|---|---|---|---|
| IC50a (nM)* | EC100b (nM) | IC50 (nM) | SIc | ||
| 3 |
|
1728 ± 3 | 429 ± 32 | 74 ± 4 | 23.35 |
| 4 |
|
249 ± 2 | 58 ± 4 | 268 ± 2 | 0.93 |
| 5 |
|
243 ± 14 | 78 ± 4 | 112 | 2.17 |
| 6a |
|
1924 ± 212 | 460 ± 110 | 82 ± 5 | 23.46 |
| 6b |
|
1609 ± 41 | 449 ± 51 | 130 ± 6 | 12.38 |
| 6c |
|
3482 ± 297 | 1177 ± 73 | 151 ± 3 | 23.06 |
| 6d |
|
255 ± 3 | 138 ± 9 | 21 ± 1 | 12.14 |
| 7a |
|
384 ± 18 | 187 ± 8 | 213 ± 2 | 1.80 |
| 7b |
|
205 ± 1 | 122 ± 11 | 14 ± 3 | 14.64 |
| 7c |
|
230 ± 5 | 51 ± 7 | 200 ± 6 | 1.15 |
| 7d |
|
1298 ± 31 | 108 ± 15 | 425 ± 17 | 3.05 |
| 8 |
|
108 ± 3 | 38 ± 2 | 116 ± 1 | 0.93 |
| Cisplatin | – | 1329 ± 82 | 589 ± 76 | 586 ± 30 | 2.26 |
*Data are presented as Mean ± SD, n = 3.
aIC50: the half maximal inhibitory concentration of the tested compound.
bEC100: the effective safe concentration value at 100% cell viability of the tested compound.
cSI: the ratio of IC50 calculated for healthy and cancer cells.